title: Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
abstract: During chronic lung infection of patients with cystic fibrosis, Pseudomonas aeruginosa can survive for long periods of time under the challenging selective pressure imposed by the immune system and antibiotic treatment as a result of its biofilm mode of growth and adaptive evolution mediated by genetic variation. Mucoidy, hypermutability and acquirement of mutational antibiotic resistance are important adaptive phenotypes that are selected during chronic P. aeruginosa infection. This review dicsusses the role played by these phenotypes for the tolerance of biofilms to antibiotics and show that mucoidy and hypermutability change the architecture of in vitro formed biofilms and lead to increase tolerance to antibiotics. Production of high levels of beta-lactamase impairs penetration of beta-lactam antibiotics due to inactivation of the antibiotic. In conclusion, these data underline the importance of biofilm prevention strategies by early aggressive antibiotic prophylaxis or therapy before phenotypic diversification during chronic lung infection of patients with cystic fibrosis.
authors.affiliation: Department of International Health, Immunology and Microbiology, Unit of Bacteriology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. ociofu@sund.ku.dk
authors.forename: Oana
authors.initials: O
authors.lastname: Ciofu
authors.forename: Lotte F
authors.initials: LF
authors.lastname: Mandsberg
authors.forename: Hengzhuang
authors.initials: H
authors.lastname: Wang
authors.forename: Niels
authors.initials: N
authors.lastname: Høiby
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics; D018441:Biofilms / Q000254:growth & development*; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D008168:Lung / Q000382:microbiology; D010641:Phenotype; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity* / Q000502:physiology*; D012641:Selection, Genetic; D047090:beta-Lactams / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams